BEDFORD, Mass. — November 4, 2025 — Leads & Copy — Ocular Therapeutix, Inc. (NASDAQ: OCUL) reported its Q3 2025 financial results and recent business highlights, including SOL-R achieving its target randomization of 555 subjects.
Recent investor day highlighted how AXPAXLI™ is positioned to redefine retina based on potential superiority label, market expansion, and immediate adoptability. SOL-R achieved target randomization of 555 subjects. Exceptional execution and retention in AXPAXLI wet AMD registrational program continue with topline data on track for SOL-1 in 1Q 2026 and SOL-R in 1H 2027. HELIOS program for AXPAXLI in NPDR expected to begin imminently using a novel primary endpoint. Cash balance of $344.8 million as of September 30, 2025, together with net proceeds of ~$445 million from October 2025 equity offering, with expected runway into 2028.
Ocular’s Executive Chairman, President, and CEO, Pravin U. Dugel, MD, expressed confidence in redefining the retina experience, citing a strong financial position and innovative clinical programs.
Recent achievements include the SOL-1 superiority trial remaining on track for Q1 2026 topline data and the SOL-R non-inferiority trial achieving its target randomization.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com
Source: Ocular Therapeutix, Inc.
